US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

10.44

+0.44004.40%

Volume:1.20M

Turnover:12.39M

Market Cap:2.09B

PE:17.14

High:10.46

Open:10.15

Low:10.06

Close:10.00

Loading ...

Overview Company News Filings

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Why Park Hotels & Resorts (PK) Is Sinking Today

Park Hotels & Resorts Is Maintained at Neutral by UBS

UBS Adjusts Price Target on Park Hotels & Resorts to $13 From $15, Keeps Neutral Rating

MT Newswires Live

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

PLX: Revisiting the Thesis

Zacks Small Cap Research

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

BofA Securities Adjusts Park Hotels & Resorts Price Target to $16 From $16.50

MT Newswires Live

Park Hotels & Resorts (PK) Receives a Buy from Compass Point

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Incannex announces results from PK study of IHL-42X

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PK/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":10.44,"timestamp":1746722173297,"preClose":10,"halted":0,"volume":1204812,"delay":0,"floatShares":195670237,"shares":199892323,"eps":0.60926,"marketStatus":"Trading","change":0.44,"latestTime":"05-08 12:36:16 EDT","open":10.15,"high":10.46,"low":10.06,"amount":12391467.32376,"amplitude":0.04,"askPrice":10.45,"askSize":507,"bidPrice":10.44,"bidSize":468,"shortable":3,"etf":0,"ttmEps":0.60926,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746734400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10,"dividendRate":0.1341,"preHourTrading":{"tag":"盘前","latestPrice":10.2,"preClose":10,"latestTime":"09:20 EDT","volume":48,"amount":486.45996,"timestamp":1746710432478},"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":10,"latestTime":"19:24 EDT","volume":183847,"amount":1838469.66,"timestamp":1746660276196},"volumeRatio":0.452794,"impliedVol":0.4708,"impliedVolPercentile":0.584},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":195670237,"roa":"2.27%","roe":"3.90%","lyrEps":1.019323,"volumeRatio":0.452794,"shares":199892323,"dividePrice":1.4,"high":10.46,"amplitude":0.04,"preClose":10,"low":10.06,"week52Low":8.27,"pbRate":"0.60","psRate":"0.80","week52High":16.58,"institutionHeld":0,"latestPrice":10.44,"committee":-0.04,"eps":0.60926,"divideRate":0.1341,"volume":1204812,"delay":0,"ttmEps":0.60926,"open":10.15,"prevYearClose":14.07,"prevWeekClose":10.26,"prevMonthClose":9.94,"prevQuarterClose":10.68,"fiveDayClose":10.04,"twentyDayClose":10.07,"sixtyDayClose":12.95},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508545690","title":"Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism","url":"https://stock-news.laohu8.com/highlight/detail?id=2508545690","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508545690?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:00","pubTimestamp":1738674000,"startTime":"0","endTime":"0","summary":"Open-label arm  has been recently reviewed by a Data Monitoring Committee  and target drug concentrations were safely reached at tested doses. DMC approved enrollment of infants into the double-blind portion of the study. sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming interim analysis. The open label arm of 8 infant participants ages 3 months to 1 year has been fully enrolled and accrued sufficient data for the DMC to review the safety and pharmacokinetics  of ersodetug, which was administered at doses of 5 or 10 mg/kg over a bi-weekly loading phase followed by a monthly maintenance phase. The task of the DMC was to independently review the safety and PK data in infants for purposes of dose confirmation, continued benefit-risk determinations, and the appropriateness of opening enrollment of the double-blind portion of the study to infant participants at the dose regimen under study. The DMC did not review glycemic efficacy and the Company remains b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rezolute-provides-phase-3-sunrize-130000992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4181","LU2360032135.SGD","BK4139","LU0029874061.USD","HI","BK4218","RZLT","LU0128526141.USD","LU2125154778.USD","LU2125154935.USD","BK4161"],"gpt_icon":0},{"id":"2508122606","title":"Why Park Hotels & Resorts (PK) Is Sinking Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2508122606","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508122606?lang=en_us&edition=fundamental","pubTime":"2025-02-04 03:14","pubTimestamp":1738610059,"startTime":"0","endTime":"0","summary":"The shares of Park Hotels & Resorts  are retreating 4% today after Swiss bank UBS lowered its 2025 EBITDA estimate for the firm by 3%-4%.UBS noted that Hawaii accounts for 32% of PK's EBITDA, and the bank does not expect the state's tourism sector to recover in 2025. Moreover, the space may not rebound in 2026 either, UBS warned.An architectural view of premium-branded hotels with the iconic company logo illuminated in the evening.Another important market for PK is New York City which accounts for 7% of the firm's EBITDA. In 2026, labor contracts are due to be renewed in the Big Apple, UBS reported, noting that the latter situation could boost PK's labor costs and result in problematic strikes.Additionally, UBS wrote that the demand for group bookings at hotels may not be as strong as expected.Park Hotels & Resorts earlier today reached a new 52-week low of $12.80, and the shares have a very high forward dividend yield of 10.4%.In the last month, PK has fallen 7%, while the shares have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-park-hotels-resorts-pk-191419729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","PK","BK4218"],"gpt_icon":0},{"id":"2508126673","title":"Park Hotels & Resorts Is Maintained at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2508126673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508126673?lang=en_us&edition=fundamental","pubTime":"2025-02-04 01:46","pubTimestamp":1738604760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2025 12:46 ET (17:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK"],"gpt_icon":0},{"id":"2508326140","title":"UBS Adjusts Price Target on Park Hotels & Resorts to $13 From $15, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2508326140","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508326140?lang=en_us&edition=fundamental","pubTime":"2025-02-04 00:03","pubTimestamp":1738598607,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts (PK) has an average rating of overweight and mean price target of $17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PK"],"gpt_icon":0},{"id":"2508114050","title":"Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114050","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114050?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial  evaluating 3 routes of administration. Phase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are supported by antiviral activity data from Invivyd's standard virologic assessments. As of Day 65, serum concentrations remain high with half-life not yet reached, indicating potential long clinical dosing interval. In vitro neutralization potency of VYD2311 assessed across contemporary SARS-CoV-2 variants tested shows an average 17-fold greater neutralization potency than pemivibart. Phase 1/2 clinical data, combined with antiviral assessment and COVID-19 antiviral correlate of protection data, including Invivyd's Phase 3 CANOPY clinical trial data for pemivibart, support a potential clinical profile for VYD2311 with superior efficacy, safety, and durability to COVID-19 vaccines:. More favorable safety and tolerability and, since VYD2311 is not a vaccin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invivyd-announces-positive-phase-1-120000411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","IVVD","BK4568","BNTX","BK4181","BK4585","BK4588","BK4139","PK","BK4535","BK4548","BK4551"],"gpt_icon":0},{"id":"2508494161","title":"PLX: Revisiting the Thesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508494161","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508494161?lang=en_us&edition=fundamental","pubTime":"2025-02-03 17:38","pubTimestamp":1738575480,"startTime":"0","endTime":"0","summary":"Protalix Biotherapeutics, Inc.  finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates in development. Its products are produced and manufactured using the ProCellEx platform which uses a plant cell line rather than the usual mammalian one, to produce its therapeutic proteins. The company recently eliminated all debt from its balance sheet and holds over $27 million in cash on its balance sheet. We expect positive free cash flow generation over the next 12 months, which should strengthen the balance sheet even further.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plx-revisiting-thesis-093800682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BD4GTV84.USD","IE00BMG7P694.USD","BK4023","IE00BMG7P926.USD","PD","PLX","PEG","IE00BMG7P587.USD","BK4218","LU1169590202.USD","PK","BK4588","BK4181","IE00BMG7P819.SGD","BK4585","IE00BD4GTT62.SGD","IE00BD4GTW91.USD","BK4139","LU1169589451.USD","BK4208"],"gpt_icon":0},{"id":"2507983957","title":"CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507983957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507983957?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod —。— Pharmacokinetic data obtained in a food-effect study in healthy volunteers in 4Q 2024 indicates that the new capsules achieved targeted mean plasma concentrations —。— Within-subject comparison of certain participants who received older capsules during the double-blind phase of the RewinD-LB trial and new capsules in the open-label extension phase indicated that participants receiving newer batch capsules, on average, achieved targeted plasma concentrations —。Measured trough plasma drug concentrations during the double-blind phase were, on average, similar to those seen with 40mg twice-daily  dosing in a previous study in Alzheimer’s Disease, a potential explanation for the current results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomed-provides-neflamapimod-dlb-program-130000031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0205194284.USD","LU0240878834.USD","LU0345774631.USD","LU0348723411.USD","PK","DLB","BK4218","LU0205193047.USD","BK4139","BK4181","LU0345774391.USD","CRVO","BK4097","LU0240877869.USD"],"gpt_icon":0},{"id":"2507763614","title":"Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2507763614","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507763614?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:00","pubTimestamp":1738159200,"startTime":"0","endTime":"0","summary":"Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions Adial’s formulation exhibited p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017232/26135/en/Adial-Pharmaceuticals-Announces-Positive-Clinical-Study-Results-from-the-AD04-103-Pharmacokinetics-Study-of-AD04-for-the-Treatment-of-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774631.USD","PK","BK4125","AUD","LU2238339852.HKD","BK4218","BK4007","LU0426412945.USD","LU1043141123.HKD","LU0426417589.USD","ADIL","BK4181","RCT","LU0994945656.USD"],"gpt_icon":0},{"id":"2507635571","title":"EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2507635571","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507635571?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:31","pubTimestamp":1738157488,"startTime":"0","endTime":"0","summary":"On Wednesday, Adial Pharmaceuticals  announced the completion of the AD04-103 pharmacokinetics  study for AD04, confirming predictable bioavailability, dose proportionality, no food effect, and a safety profile consistent with ondansetron's use.These results enable an End-of-Phase 2  FDA interaction to finalize the Phase 3 trial design and support ongoing partnership discussions.AD04, a selective 5-HT3 antagonist for Alcohol Use Disorder , is being developed for patients with a 5-HT3 genomic biomarker and follows a micro-dosing regimen under the FDA's 505 pathway.Cohort 1 (n=6): Assessed PK variability at 0.33 mg and 0.99 mg doses.Cohort 2 : Evaluated bioavailability vs. ondansetron 4 mg, dose proportionality, and food effect.Related: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder. This article EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder originally appeared ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-reveals-positive-133128619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUD","BK4007","PK","BK4181","LU0994945656.USD","BK4218","BK4125","LU0426412945.USD","LU0345774631.USD","LU2238339852.HKD","ADIL","LU0426417589.USD","LU1043141123.HKD"],"gpt_icon":0},{"id":"2506151936","title":"Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2506151936","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506151936?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:05","pubTimestamp":1738073100,"startTime":"0","endTime":"0","summary":"European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP cover","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016487/0/en/Sonnet-BioTherapeutics-Further-Expands-Global-Intellectual-Property-Portfolio-with-Issuance-of-EU-Patent-for-FHAB-Platform-Technology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4139","SONN","BK4156","BK4218","BK4007","PROC","BK4181"],"gpt_icon":0},{"id":"2506019113","title":"BofA Securities Adjusts Park Hotels & Resorts Price Target to $16 From $16.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2506019113","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506019113?lang=en_us&edition=fundamental","pubTime":"2025-01-27 23:59","pubTimestamp":1737993594,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts (PK) has an average rating of overweight and mean price target of $17.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PK"],"gpt_icon":0},{"id":"2506374734","title":"Park Hotels & Resorts (PK) Receives a Buy from Compass Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2506374734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506374734?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:16","pubTimestamp":1737983787,"startTime":"0","endTime":"0","summary":"Compass Point analyst Floris van Dijkum maintained a Buy rating on Park Hotels & Resorts (PK – Research Report) today and set a price target of $20...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/park-hotels-resorts-pk-receives-a-buy-from-compass-point?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/park-hotels-resorts-pk-receives-a-buy-from-compass-point?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4181","BK4218","PK"],"gpt_icon":0},{"id":"2505109026","title":"Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2505109026","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505109026?lang=en_us&edition=fundamental","pubTime":"2025-01-24 05:05","pubTimestamp":1737666300,"startTime":"0","endTime":"0","summary":"Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014608/0/en/Larimar-Therapeutics-Announces-Dosing-of-Adolescents-in-Nomlabofusp-Pediatric-Pharmacokinetic-Run-In-Study-for-Patients-with-Friedreich-s-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FA","BK4535","BK4218","PK","BK4181","BK4539","LENZ","BK4139","BK4130"],"gpt_icon":0},{"id":"2505018774","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505018774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505018774?lang=en_us&edition=fundamental","pubTime":"2025-01-23 21:15","pubTimestamp":1737638100,"startTime":"0","endTime":"0","summary":"SEATTLE, Jan. 23, 2025  -- Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows:. As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we continued to demonstrate the broad utility of -endoxifen as an innovative therapy that has the potential to transform the breast cancer treatment landscape.Completion of the KARISMA-Endoxifen Phase 2 Study - One of the most significant milestones this year was the completion and announcement of results from our phase 2 KARISMA-Endoxifen Study. This study evaluated the ability of low doses o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-therapeutics-issues-letter-shareholders-131500934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4079","BK4551","FTV","E","BK4218","BK4548","BK4139","BK4543","BK4135","IE00BN0W2W23.USD","BK4161","Z","LU1496350502.SGD","BK4201","LU1496350171.SGD","BK4181","IE00BN0W2V16.EUR","PK","ATOS","LENZ","OFS","IE00BN0W2T93.GBP","BK4588"],"gpt_icon":0},{"id":"2505973340","title":"Incannex announces results from PK study of IHL-42X","url":"https://stock-news.laohu8.com/highlight/detail?id=2505973340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505973340?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:35","pubTimestamp":1737635722,"startTime":"0","endTime":"0","summary":"Incannex (IXHL) Healthcare announced positive topline results from a completed pharmacokinetics, PK, and safety study of IHL-42X, a novel, oral fix...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incannex-announces-results-from-pk-study-of-ihl-42x?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incannex-announces-results-from-pk-study-of-ihl-42x?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IXHL","BK4181","BK4218","PK"],"gpt_icon":0},{"id":"2505092779","title":"Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea","url":"https://stock-news.laohu8.com/highlight/detail?id=2505092779","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505092779?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:30","pubTimestamp":1737635400,"startTime":"0","endTime":"0","summary":"Demonstrated bioavailability of IHL-42X, Incannex’s proprietary combination formulation, confirming delivery of both dronabinol and acetazolamideAchieved similar PK and equivalent total drug exposure ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014173/0/en/Incannex-Healthcare-Announces-Positive-Topline-Results-from-Pharmacokinetics-PK-Study-of-IHL-42X-an-Oral-Combination-Medicine-for-the-Treatment-of-Obstructive-Sleep-Apnea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","HCSG","BK4218","BK4085","BK4137","BK4563","BK4181","BK4097","BK4510","IH","AHI","BK4167"],"gpt_icon":0},{"id":"2505948630","title":"Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2505948630","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505948630?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention. NEWTOWN, Pa., Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced completion of Phase I clinical studies of its investigational one-dose influenza  therapy, tivoxavir marboxil , for the treatment or prevention of H5N1 bird flu.\"We believe that our clinical data in healthy volunteers support accelerated development of tivoxavir marboxil in response to the growing threat of bird flu,\" said Werner Cautreels, PhD, Chief Executive Officer of Traws Pharma.About Tivoxavir MarboxilSeasonal influenza represents an estimated multi-billion antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders1, with upside potential from pandemic flu ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/traws-pharma-announces-completion-phase-120000809.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-announces-completion-phase-120000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4181","BK4218","LU1169589451.USD","LU1169590202.USD","TRAW","BK4023","CDC","CEN","BK4007","PD"],"gpt_icon":0},{"id":"2505831094","title":"SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2505831094","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505831094?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST. MIAMI, Jan. 23, 2025  -- SAB BIO , , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin  for delaying the onset or progression of type 1 diabetes , announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader  Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sab-bio-announces-r-d-120000937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","PK","BK4181","BK4121","BK4588","KOL","BIO","SABS","BK4218","BK4585","PD","LU1169589451.USD","SABSW","BK4023"],"gpt_icon":0},{"id":"2505094867","title":"Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2505094867","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505094867?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease  -. - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement –。WATERTOWN, Mass., Jan. 23, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of AD. Collectively, the safety, tolerability, pharmacokinetic , and pharmacodynamic  profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a potential once-daily oral therapy for AD.Achieved robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid  demonstrating a strong PK/PD relationship, sustained target engagement ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-reports-positive-data-120000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARIA","CSF","LU1169590202.USD","BK4023","LU1169589451.USD","BK4081","VG","BK4139","BK4563","VIGL","PAM","PD","PK","BK4218","BK4181"],"gpt_icon":0},{"id":"2505740649","title":"Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2505740649","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505740649?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc.  , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has secured buy-out rights and exclusive licensing for two patented anticancer drugs targeting, among others, prostate, ovarian, and colorectal cancers.Both of these innovative anticancer therapies, developed through cutting-edge oncology research, are protected by international patents and set to commence Clinical Phase I trials. The first therapy is safeguarded by a WIPO patent  and is valid in key markets including the EU, USA, Canada, Japan, China, and Australia. The second therapy is covered by an EU patent  and has been internationally filed under WO 2018/011414 A1, with a focus on major markets such as the USA, Canada, Japan, China, and Australia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosmos-health-secures-two-wipo-130000163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2092937221.SGD","BK4175","BK4161","BK4181","BK4567","BK4218","A","BK4121","IE00BN0W2W23.USD","LU2041044095.USD","LU2413666426.HKD","MSS","BK4585","BK4159","BK4588","IE00BN0W2T93.GBP","LU0347712357.USD","LU1721428933.USD","COSM","LU2413666699.HKD","B","IE00BN0W2V16.EUR","LU1165135440.EUR","BK4113","PK","CAGR","LU1543694498.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2025-06-30","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-30","defaultRemindTime":1751290200000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-15","payableDate":"2025-06-30","currency":"USD","dateTimestamp":1751256000000,"payDate":"2025-07-15"},{"market":"US","date":"2025-05-05","symbol":"PK","fiscalQuarterEnding":"2025/03","expectedEps":0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746417600000,"reportTimeType":"pre","actualEps":0.46},{"date":"2025-03-31","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-15"},{"date":"2025-02-19","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.37,"defaultRemindTime":1739998800000,"name":null,"time":"Post Market","dateTimestamp":1739941200000,"actualEps":null},{"date":"2024-12-31","symbol":"PK","amount":0.65,"announcedDate":"2024-11-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-31","defaultRemindTime":1735655400000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-15","payableDate":"2024-12-31","currency":"USD","dateTimestamp":1735621200000,"payDate":"2025-01-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.25,"hold":0.5625,"sell":0.0625,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.5625,"analysts":16,"updateTime":1746072000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2025-05-07","current":15.613637,"percent":0.826623,"low":-68.24471,"twenty":-10.159473,"median":-3.675279,"eighty":11.52593,"high":55.399897,"avg":-2.764185,"sd":27.214691,"marketCap":1982931844},"quantilePoints":[{"date":"2020-05-08","current":6.844479,"twenty":11.80177,"median":14.646936,"eighty":31.785807,"marketCap":2094410636},{"date":"2020-05-15","current":-3.602916,"twenty":11.684678,"median":14.629627,"eighty":31.749191,"marketCap":1722193974},{"date":"2020-05-22","current":-4.628096,"twenty":11.308585,"median":14.609077,"eighty":31.647673,"marketCap":2212230016},{"date":"2020-05-29","current":-4.844961,"twenty":11.239782,"median":14.592668,"eighty":31.498937,"marketCap":2315891487},{"date":"2020-06-05","current":-6.446805,"twenty":11.167874,"median":14.571217,"eighty":31.464863,"marketCap":3081572803},{"date":"2020-06-12","current":-5.712421,"twenty":11.131908,"median":14.542822,"eighty":31.43819,"marketCap":2730537369},{"date":"2020-06-19","current":-5.278691,"twenty":11.055905,"median":14.514879,"eighty":31.414917,"marketCap":2523214428},{"date":"2020-06-26","current":-4.682313,"twenty":10.886453,"median":14.495498,"eighty":31.375334,"marketCap":2238145384},{"date":"2020-07-02","current":-4.746386,"twenty":10.800505,"median":14.4813,"eighty":31.352562,"marketCap":2268772637},{"date":"2020-07-10","current":-4.756244,"twenty":10.682725,"median":14.429243,"eighty":31.344509,"marketCap":2273484522},{"date":"2020-07-17","current":-4.514735,"twenty":7.464564,"median":14.377186,"eighty":31.340758,"marketCap":2158043339},{"date":"2020-07-24","current":-4.204224,"twenty":6.899423,"median":14.324128,"eighty":31.317149,"marketCap":2009618961},{"date":"2020-07-31","current":-4.076076,"twenty":6.656099,"median":14.175607,"eighty":31.295818,"marketCap":1948364455},{"date":"2020-08-07","current":-2.566048,"twenty":6.428473,"median":14.137595,"eighty":31.259301,"marketCap":2101593620},{"date":"2020-08-14","current":-2.721392,"twenty":6.26364,"median":14.089266,"eighty":31.247128,"marketCap":2228820140},{"date":"2020-08-21","current":-2.525774,"twenty":6.153752,"median":14.006744,"eighty":31.247128,"marketCap":2068608967},{"date":"2020-08-28","current":-2.870982,"twenty":5.863333,"median":13.870814,"eighty":31.210909,"marketCap":2351334566},{"date":"2020-09-04","current":-3.046463,"twenty":5.667103,"median":13.801033,"eighty":31.128278,"marketCap":2495053412},{"date":"2020-09-11","current":-2.902626,"twenty":5.384533,"median":13.774657,"eighty":31.118835,"marketCap":2377251079},{"date":"2020-09-18","current":-3.095368,"twenty":4.792705,"median":13.714879,"eighty":31.059812,"marketCap":2535106206},{"date":"2020-09-25","current":-2.819201,"twenty":2.477694,"median":13.678818,"eighty":30.998429,"marketCap":2308925726},{"date":"2020-10-02","current":-3.046463,"twenty":2.452731,"median":13.647472,"eighty":30.967738,"marketCap":2495053412},{"date":"2020-10-09","current":-3.103998,"twenty":2.419945,"median":13.625211,"eighty":30.925242,"marketCap":2542174346},{"date":"2020-10-16","current":-2.865229,"twenty":2.407631,"median":13.604071,"eighty":30.830806,"marketCap":2346622473},{"date":"2020-10-23","current":-3.106875,"twenty":2.39881,"median":13.60157,"eighty":30.809558,"marketCap":2544530392},{"date":"2020-10-30","current":-2.856599,"twenty":2.384831,"median":13.570144,"eighty":30.743453,"marketCap":2339554333},{"date":"2020-11-06","current":-2.206192,"twenty":2.293797,"median":13.511461,"eighty":30.717484,"marketCap":2426811706},{"date":"2020-11-13","current":-3.043689,"twenty":2.260846,"median":13.488575,"eighty":30.70568,"marketCap":3348057703},{"date":"2020-11-20","current":-3.221469,"twenty":2.22504,"median":13.471041,"eighty":30.674988,"marketCap":3543616316},{"date":"2020-11-27","current":-3.581314,"twenty":2.209754,"median":13.450169,"eighty":30.667905,"marketCap":3939445798},{"date":"2020-12-04","current":-3.885469,"twenty":2.206595,"median":13.437336,"eighty":30.660823,"marketCap":4274015956},{"date":"2020-12-11","current":-3.77623,"twenty":2.197164,"median":13.4098,"eighty":30.634853,"marketCap":4153853434},{"date":"2020-12-18","current":-3.649856,"twenty":2.188516,"median":13.398907,"eighty":30.606523,"marketCap":4014841890},{"date":"2020-12-24","current":-3.681985,"twenty":2.181468,"median":13.390367,"eighty":30.587635,"marketCap":4050183808},{"date":"2020-12-31","current":-3.673418,"twenty":2.165633,"median":13.373288,"eighty":30.559305,"marketCap":4040759297},{"date":"2021-01-08","current":-3.726966,"twenty":2.127386,"median":13.357167,"eighty":30.487456,"marketCap":4099662493},{"date":"2021-01-15","current":-3.711972,"twenty":2.090996,"median":13.34366,"eighty":30.406499,"marketCap":4083169598},{"date":"2021-01-22","current":-3.889753,"twenty":2.071846,"median":13.334859,"eighty":30.325661,"marketCap":4278728211},{"date":"2021-01-29","current":-3.572747,"twenty":2.068781,"median":13.320798,"eighty":30.089882,"marketCap":3930021287},{"date":"2021-02-05","current":-3.887611,"twenty":2.05882,"median":13.314589,"eighty":29.899013,"marketCap":4276372084},{"date":"2021-02-12","current":-4.215327,"twenty":2.034301,"median":13.288201,"eighty":29.854103,"marketCap":4636859648},{"date":"2021-02-19","current":-4.444514,"twenty":2.013845,"median":13.280132,"eighty":29.737337,"marketCap":4888965330},{"date":"2021-02-26","current":-3.563311,"twenty":-2.231897,"median":13.271323,"eighty":29.699163,"marketCap":5131167540},{"date":"2021-03-05","current":-3.448497,"twenty":-2.455006,"median":13.256856,"eighty":29.625061,"marketCap":4965836198},{"date":"2021-03-12","current":-3.740659,"twenty":-2.561446,"median":13.245191,"eighty":29.508294,"marketCap":5386549593},{"date":"2021-03-19","current":-3.755425,"twenty":-2.654652,"median":13.226158,"eighty":29.474611,"marketCap":5407812650},{"date":"2021-03-26","current":-3.589648,"twenty":-2.723118,"median":13.200933,"eighty":29.409492,"marketCap":5169093647},{"date":"2021-04-01","current":-3.581442,"twenty":-2.747858,"median":13.188305,"eighty":29.387036,"marketCap":5157275875},{"date":"2021-04-09","current":-3.522353,"twenty":-2.785256,"median":13.150762,"eighty":29.281497,"marketCap":5072187914},{"date":"2021-04-16","current":-3.497732,"twenty":-2.84164,"median":13.078426,"eighty":29.200659,"marketCap":5036734596},{"date":"2021-04-23","current":-3.597855,"twenty":-2.856599,"median":13.071715,"eighty":29.043473,"marketCap":5180911420},{"date":"2021-04-30","current":-3.661868,"twenty":-2.86063,"median":13.065856,"eighty":28.92446,"marketCap":5273090044},{"date":"2021-05-07","current":-5.611001,"twenty":-2.872133,"median":13.00038,"eighty":27.600316,"marketCap":5285562943},{"date":"2021-05-14","current":-5.538196,"twenty":-2.918736,"median":12.98625,"eighty":26.702293,"marketCap":5216980694},{"date":"2021-05-21","current":-5.07124,"twenty":-2.973394,"median":12.984113,"eighty":26.504319,"marketCap":4777108342},{"date":"2021-05-28","current":-5.219361,"twenty":-3.010216,"median":12.953043,"eighty":26.370989,"marketCap":4916637744},{"date":"2021-06-04","current":-5.151577,"twenty":-3.032655,"median":12.935438,"eighty":26.342707,"marketCap":4852785306},{"date":"2021-06-11","current":-5.407649,"twenty":-3.066646,"median":12.921003,"eighty":26.23968,"marketCap":5094005628},{"date":"2021-06-18","current":-5.181703,"twenty":-3.103007,"median":12.910479,"eighty":26.122512,"marketCap":4881164167},{"date":"2021-06-25","current":-5.407649,"twenty":-3.130464,"median":12.883118,"eighty":26.110391,"marketCap":5094005628},{"date":"2021-07-02","current":-5.103877,"twenty":-3.201231,"median":12.837305,"eighty":26.041706,"marketCap":4807852108},{"date":"2021-07-09","current":-4.933162,"twenty":-3.220989,"median":12.808486,"eighty":25.863933,"marketCap":4647038560},{"date":"2021-07-16","current":-4.616837,"twenty":-3.39668,"median":12.795175,"eighty":25.55283,"marketCap":4349060515},{"date":"2021-07-23","current":-4.684621,"twenty":-3.442298,"median":12.778454,"eighty":25.461924,"marketCap":4412912953},{"date":"2021-07-30","current":-4.644453,"twenty":-3.472857,"median":12.762007,"eighty":25.27203,"marketCap":4375074472},{"date":"2021-08-06","current":-5.555659,"twenty":-3.499046,"median":12.754728,"eighty":25.175063,"marketCap":4438971639},{"date":"2021-08-13","current":-5.472783,"twenty":-3.515459,"median":12.739067,"eighty":25.092237,"marketCap":4372753628},{"date":"2021-08-20","current":-5.209355,"twenty":-3.540249,"median":12.712634,"eighty":25.013451,"marketCap":4162274952},{"date":"2021-08-27","current":-5.74509,"twenty":-3.546559,"median":12.705805,"eighty":24.987189,"marketCap":4590327091},{"date":"2021-09-03","current":-5.52902,"twenty":-3.565932,"median":12.702277,"eighty":24.944766,"marketCap":4417687278},{"date":"2021-09-10","current":-5.437265,"twenty":-3.571599,"median":12.695796,"eighty":24.807396,"marketCap":4344374481},{"date":"2021-09-17","current":-5.688853,"twenty":-3.581314,"median":12.675381,"eighty":24.746792,"marketCap":4545393441},{"date":"2021-09-24","current":-5.97004,"twenty":-3.589648,"median":12.636863,"eighty":24.72659,"marketCap":4770061692},{"date":"2021-10-01","current":-5.896043,"twenty":-3.599497,"median":12.622139,"eighty":24.665986,"marketCap":4710938468},{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-25","current":9.512373,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2016623108},{"date":"2025-05-02","current":9.559983,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2026716317},{"date":"2025-05-07","current":15.613637,"twenty":-10.159473,"median":-3.675279,"eighty":11.52593,"marketCap":1982931844}],"updateTime":1746722176584}}}